Introduction: Over the past 15 years, direct oral anticoagulant (DOAC) drugs have replaced
vitamin K antagonists in a number of indications requiring oral anticoagulant therapy …

Thrombo-embolism of the venous system consisting of deep vein thrombosis (DVT) and
pulmonary embolism (PE) is common and associated with high morbidity and mortality …

Thromboembolic disease (TD) is a relatively common disease with acute risk of death and
potential long-term consequences in term of postthrombotic syndrome or chronic pulmonary …

One of the main innovation emerged in recent years in the field of venous thromboembolism
(VTE) has been represented by the clinical development and marketing of new oral …

Venous thromboembolism (VTE), consisting of deep vein thrombosis and pulmonary
embolism, is a major clinical concern associated with significant morbidity and mortality. The …

The milestone of treating and preventing venous thromboembolism (VTE) is the application
of anticoagulants. For many years the cornerstone was the use of vitamin K antagonists …

Venous thromboembolic disease, which includes pulmonary thromboembolism and deep
vein thrombosis, is one of the most common causes of morbidity and mortality. Management …

The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs)
for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which …

Pulmonary embolism (PE) is a relatively common cardiovascular emergency. PE and deep
vein thrombosis (DVT) are considered expressions of the same disease, termed as venous …

Venous thromboembolism (VTE) is still an important problem of Public Health, due to its
impact in terms of morbidity, mortality, resource allocation and associated costs. In the …